Immunotherapy improves lung cancer survival by harnessing the body’s immune system to recognize and attack cancer cells. Drugs like immune checkpoint inhibitors block signals that cancer cells use to evade the immune response, allowing the immune system to target and destroy them. This approach has shown remarkable success, leading to longer survival and even durable responses in some patients. Immunotherapy offers a promising avenue for enhancing treatment outcomes in lung cancer and has transformed the landscape of cancer therapy.
